Last edition
News about " investigational immunotherapy "
Philogen Resubmits EMA Marketing Application for Melanoma Therapy Nidlegy with Updated Phase 3 Data
Philogen has resubmitted its EMA marketing application for investigational melanoma therapy Nidlegy, supported by updated Phase 3 clinical data demonstrating reduced risk of relapse or death and an extended patient follow-up period.
Investigational Immunotherapy | 28/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members